Kristyn Rene Aalto
Directeur Général chez Orlance, Inc.
Profil
Kristyn Rene Aalto is currently the Chief Executive Officer at Orlance, Inc. and also holds the position of Principal at the University of Michigan, Bard Access Systems, Inc., and Leibinger LP.
Previously, she was the President, Chief Executive Officer & Director at Aursos, Inc. and a Principal at Accord Biosciences, Inc. She also served as an Entrepreneur-in-Residence at Arboretum Ventures LLC from 2007 to 2008.
Ms. Aalto completed her undergraduate degree at Marquette University.
Postes actifs de Kristyn Rene Aalto
| Sociétés | Poste | Début |
|---|---|---|
Bard Access Systems, Inc.
 Bard Access Systems, Inc. Medical SpecialtiesHealth Technology Bard Access Systems, Inc. develops, manufactures and distributes medical devices. It makes vascular access products as dialysis & pheresis catheters, implanted ports, ultrasound systems and surgical accessories. The company was founded in 1947 and is headquartered in Salt Lake City, UT. | Corporate Officer/Principal | 27/10/2009 |
| Leibinger LP | Corporate Officer/Principal | 27/10/2009 |
| University of Michigan | Corporate Officer/Principal | 27/10/2009 |
| Orlance, Inc. | Directeur Général | - |
Anciens postes connus de Kristyn Rene Aalto
| Sociétés | Poste | Fin |
|---|---|---|
Arboretum Ventures LLC
 Arboretum Ventures LLC Investment ManagersFinance Arboretum Ventures LLC (Arboretum Ventures) is a venture capital firm founded in 2002 by Jan L. Garfinkle and Tim B. Petersen. The firm is headquartered in Ann Arbor, Michigan. | Corporate Officer/Principal | 30/09/2008 |
Aursos, Inc.
 Aursos, Inc. Pharmaceuticals: MajorHealth Technology Aursos, Inc. develops and markets biopharmaceutical products. The company was founded by Seth Donahue and Ronald J. Shebuski Sr. in March 2007 and is headquartered in Kalamazoo, MI. | Directeur Général | - |
Accord Biosciences, Inc.
 Accord Biosciences, Inc. Electronic Equipment/InstrumentsElectronic Technology Accord Biomaterials, Inc., based in Ann Arbor, MI, focuses upon the development of Nogen nitric oxide materials for use in biomarker assays, diagnostic tools and blood-contacting medical devices. Nogen materials liberate nitric oxide from carrier molecules within blood known as nitrosothiols ('RSNOs'), enabling the development of tools that precisely quantitative RSNO levels in blood and vascular device coatings that resist clotting and infection due to nitric oxide's inherent antiplatelet and antimicrobial effects. Accord collaborates with incubator MC3 Corporation, the Cleveland Clinic and best-in-class development partners and holds an exclusive license to Nogen technology from the University of Michigan. Privately-held and venture-backed, Accord is committed to accelerating clinical validation and utility of this technology. | President | - |
Formation de Kristyn Rene Aalto
| Marquette University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Aursos, Inc.
Aursos, Inc. Pharmaceuticals: MajorHealth Technology Aursos, Inc. develops and markets biopharmaceutical products. The company was founded by Seth Donahue and Ronald J. Shebuski Sr. in March 2007 and is headquartered in Kalamazoo, MI. | Health Technology |
Bard Access Systems, Inc.
Bard Access Systems, Inc. Medical SpecialtiesHealth Technology Bard Access Systems, Inc. develops, manufactures and distributes medical devices. It makes vascular access products as dialysis & pheresis catheters, implanted ports, ultrasound systems and surgical accessories. The company was founded in 1947 and is headquartered in Salt Lake City, UT. | Health Technology |
Accord Biosciences, Inc.
Accord Biosciences, Inc. Electronic Equipment/InstrumentsElectronic Technology Accord Biomaterials, Inc., based in Ann Arbor, MI, focuses upon the development of Nogen nitric oxide materials for use in biomarker assays, diagnostic tools and blood-contacting medical devices. Nogen materials liberate nitric oxide from carrier molecules within blood known as nitrosothiols ('RSNOs'), enabling the development of tools that precisely quantitative RSNO levels in blood and vascular device coatings that resist clotting and infection due to nitric oxide's inherent antiplatelet and antimicrobial effects. Accord collaborates with incubator MC3 Corporation, the Cleveland Clinic and best-in-class development partners and holds an exclusive license to Nogen technology from the University of Michigan. Privately-held and venture-backed, Accord is committed to accelerating clinical validation and utility of this technology. | Electronic Technology |
| Leibinger LP | |
| Orlance, Inc. | |
Arboretum Ventures LLC
Arboretum Ventures LLC Investment ManagersFinance Arboretum Ventures LLC (Arboretum Ventures) is a venture capital firm founded in 2002 by Jan L. Garfinkle and Tim B. Petersen. The firm is headquartered in Ann Arbor, Michigan. | Finance |